Eupraxia Pharmaceuticals announces treatment outcomes for EP-104GI

Eupraxia Pharmaceuticals (EPRX) announced positive treatment outcomes from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Nine-month data was collected for the first time in the RESOLVE study in Cohort 5. Each patient in Cohort 5 received 12 injections of 4 mg EP-104GI delivered to the lower two-thirds of the esophagus. Results at 36 weeks include: Symptom Improvement: All three patients reported reduced symptom severity. Peak improvements reached up to a 5-point reduction, with an average reduction of 3.7 points on the SDI. Tissue Health: Improvements in esophageal tissue health were sustained, with an average 56% reduction in EoEHSS Stage score and a 45% reduction in Grade score. Reductions in Eosinophils: Reductions in eosinophil counts were maintained, with a mean decrease of 77% across a standard number of biopsy sites within the treated area. The mean remission rate across all biopsy sites was 52%. Notably, one patient maintained complete histologic remission-defined as all sites showing less than or equal to 6 eosinophils per high-power field-originally achieved at 3 months and sustained through 9 months. Safety outcomes: Plasma levels of fluticasone remained steady and predictable, well below levels typically observed with daily asthma inhalers. No serious adverse events were reported.